Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS

by Roberta Ottria, Alessandro Ravelli, Matteo Miceli, Sara Casati, Marica Orioli, Pierangela Ciuffreda
Published 2019-03-01

Profile of olaparib in the treatment of advanced ovarian cancer

by Chase DM, Patel S, Shields K
Published 2016-04-01

The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice

by S V Khokhlova
Published 2016-12-01

Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer

by S V Khokhlova
Published 2017-09-01

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

by Soupos Nikolaos, Laschos Konstantinos, Bournakis Evangelos, Kostouros Euthymios, Aravantinos Gerasimos
Published 2015-09-01

International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

by V. B. Matveev, O. A. Khalmurzaev, O. I. Evsyukova
Published 2021-02-01

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

by Hye Jeong Park, Jun Sang Bae, Kyoung Min Kim, Young Jae Moon, See-Hyoung Park, Sang Hoon Ha, Usama Khamis Hussein, Zhongkai Zhang, Ho Sung Park, Byung-Hyun Park, Woo Sung Moon, Jung Ryul Kim, Kyu Yun Jang
Published 2018-05-01

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

by Montemorano L, Lightfoot MDS, Bixel K
Published 2019-12-01

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy

by Toko Kumeta, Ryoichi Matsunuma, Kei Yamaguchi, Ryosuke Hayami, Michiko Tsuneizumi
Published 2019-10-01

Ovarian cancer molecular stratification and tumour heterogeneity; a necessity and a challenge

by Stefan eSymeonides, Charlie eGourley
Published 2015-10-01

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials

by Alecu I, Milenkova T, Turner SR
Published 2018-02-01

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer

by Wu M, Liu J, Hu C, Li D, Yang J, Wu Z, Yang L, Chen Y, Fu S, Wu J
Published 2018-12-01

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation

by Li X, Gao L, Qiu M, Cao D
Published 2021-04-01

The latest first-line treatment options for ovarian cancer: focus on maintenance therapy

by A. A. Rumyantsev
Published 2020-12-01

Successful olaparib desensitization using a novel one-day protocol

by Rongbo Zhu, Stephen Welch, Hannah Roberts
Published 2020-11-01

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

by Jing Ni, Xianzhong Cheng, Rui Zhou, Xia Xu, Wenwen Guo, Xiaoxiang Chen
Published 2019-11-01

Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report

by Pramod Kumar Julka, Amit Verma, Kush Gupta
Published 2020-02-01

PARP inhibitors in female reproductive system cancers

by I A Pokataev, S A Tyulyandin
Published 2017-06-01

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

by Fatima Karzai, David VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel, Maria J. Merino, Ryan Dittamore, Jennifer Marté, Renee N. Donahue, Jeffrey Schlom, Keith J. Killian, Paul S. Meltzer, Seth M. Steinberg, James L. Gulley, Jung-Min Lee, William L. Dahut
Published 2018-12-01

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report

by Cheng Y, Zhang J, Qin SK, Hua HQ
Published 2018-09-01